Structural heart disease is not always a one valve problem. In today’s world of rapid transcatheter innovation, new clinical trials for aortic, mitral, and tricuspid valve disease are changing lives. Patients who once had no options now have real hope through structural heart clinical trials and transcatheter therapies. Innovation is moving fast, and that is something to celebrate. But here is the question we need to start asking: what happens when a patient who joined one he

Tricuspid Valve Regurgitation, Explained in Plain Language I’m listening to a non-invasive cardiologist explain tricuspid valve regurgitation (TR) grades, and I hear this a lot: “Mild” and “trace” are clinically irrelevant.They don’t matter. I understand what that means medically .But here’s the truth — it still matters to patients. Let me explain why 👇 🩺 What Doctors Are Taught In medical training and guidelines: Trace or mild TR is very common Many healthy people have i

How a Century-Old Mindset Still Shapes the Way Patients Are Seen and Heard I’ve been thinking a lot about why the doctor–patient relationship can feel so distant.And when you peel back the layers, it goes way back — more than a hundred years. Where This All Started Around 1910, the Flexner Report reshaped medical training across the U.S.It pushed a strict “science first, emotions last” model. By the 1920s–1950s, that mindset had become the blueprint. Doctors were taught to:

Simply because connection was never the system’s design goal in the first place. 📱 Today I got a notification in MyChart — that little ping that’s supposed to make managing your care easier. It told me to schedule my final clinical trial appointment. So, I followed the instructions. I scheduled my echo. A few minutes later, the phone rang — it was the clinical site coordinator asking to reschedule the appointment I just made. Turns out, the doctor assigned to my study is onl